Navigation Links
Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
Date:3/6/2008

BOTHELL, Wash., March 6 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it aligned the power of its leading product brands (Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R)), squarely behind the Cardiac Science(TM) brand.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO)

"We believe our solitary focus on noninvasive cardiology elevates our product and service offerings and differentiates us in the medical devices field," said John Hinson, Cardiac Science president and chief executive officer. "Going forward, our 95-year heritage and track record, comprehensive product and service offerings, and the strengths of our predecessor companies will be concentrated into a single, overarching story of dependability."

"Our products, employees, and culture are rooted in dependability," began Allan Criss, senior vice president of sales, marketing, and service. "The new Cardiac Science identity communicates our promise more clearly: We intend to be the company the global community thinks of first for high-quality noninvasive products and services. Our customers can -- and do -- depend on us, no matter what."

The new "shielded heart" logo represents the protective nature of the business. Cardiac Science products diagnose heart disease, resuscitate victims of sudden cardiac arrest, and help people get on with their lives with top-of-the-line cardiac rehabilitative equipment. The orange color represents the warmth, energy, and approachability of the brand.

"The compan
'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business
2. New research shows that iPods do not interfere with cardiac pacemakers
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
5. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
6. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
7. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
8. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
9. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
10. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
11. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2Tropical birds waited for land crossing between North and South America: UBC study 2U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 1U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 2U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 3CardioNet Terminates Merger With Biotel 51633 1Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 1Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 2Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 3Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 4Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 5Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 6Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 7Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 8Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 9